ReviewCancers2023
The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0.Journal for immunotherapy of cancer · 2026Guideline
- Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4.Frontiers in immunology · 2024Trial
- Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy.Journal of comparative effectiveness research · 2026Observational
- Transitioning CAR-T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta-cel in Germany.HemaSphere · 2026Article
- Quality of Life in CAR-T Cell Therapy.Hematology reports · 2026Review
- Willingness to Pay for Treatment Attributes in Diffuse Large B-Cell Lymphoma: A Discrete Choice Experiment in Japan.Clinical drug investigation · 2026Article
- Outcomes of point-of-care manufactured CAR T cell therapy for B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in Vietnam.Molecular therapy. Oncology · 2026Article
- Review
- Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice.Frontiers in oncology · 2026Article
- Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings.Advances in hematology · 2026Review
- Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysis.Journal of managed care & specialty pharmacy · 2025Article
- Advancement of clinical practice in delivering CAR T-cell therapy: impact on healthcare resource utilization and comparison with autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas.Annals of hematology · 2025Article
- Baby you can drive my CAR-T cells.Lupus · 2025Review
- Establishing a successful outpatient CAR T-Cell program with cilta-cel: real-world experience from an expert roundtable.Future oncology (London, England) · 2025Review
- T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany.Bone marrow transplantation · 2025Article
- Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.American journal of cancer research · 2025Article
- Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention.Blood advances · 2024Article
- Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma.Advances in therapy · 2024Article
- Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma.Frontiers in immunology · 2024Article
- How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspective.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Although chimeric antigen receptor (CAR)-T cell therapies are typically administered in the inpatient setting, outpatient administration is rapidly expanding. However, there is limited summarized evidence comparing outcomes between outpatient and inpatient administration. This systematic literature review aims to compare the safety, efficacy, quality of life (QoL), costs, and healthcare resource utilization (HCRU) outcomes in patients with hematological cancer who are administered CAR-T therapy in an outpatient versus an inpatient setting. Publications (2016 or later) that reported the outcomes of interest in patients treated with a CAR-T therapy in both outpatient and inpatient settings, or only the outpatient setting, were reviewed. In total, 38 publications based on 21 studies were included. Safety findings suggested the comparable frequency of adverse events in the two settings. Eleven studies that reported data in both settings showed comparable response rates (80-82% in outpatient and 72-80% in inpatient). Improvements in the QoL were observed in both settings while costs associated with CAR-T therapy were lower in the outpatient setting. Although unplanned hospitalizations were higher in the outpatient cohort, overall HCRU was lower. Outpatient administration of CAR-T therapy appears to have comparable outcomes in safety, efficacy, and QoL to inpatient administration while reducing the economic burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.